Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

14.92
+0.56003.90%
Post-market: 14.950.0300+0.20%19:48 EDT
Volume:626.16K
Turnover:9.28M
Market Cap:1.38B
PE:-14.19
High:15.02
Open:14.57
Low:14.40
Close:14.36
52wk High:15.02
52wk Low:3.06
Shares:92.33M
Float Shares:63.79M
Volume Ratio:1.47
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0517
EPS(LYR):-0.5300
ROE:-141.68%
ROA:-25.71%
PB:31.27
PE(LYR):-28.15

Loading ...

Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT

TIPRANKS
·
May 11

Alpha Tau Says Complete Response in 2 Brain Cancer Patients Observed in Interim Trial of Radiation Treatment

MT Newswires Live
·
May 11

Alpha Tau Alpha DaRT glioblastoma trial shows 67% complete response in interim data

Reuters
·
May 11

Alpha Tau Announces Groundbreaking Interim Results From Its U.S. Alpha Dart® Recurrent Glioblastoma Trial, With 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30Am Et

THOMSON REUTERS
·
May 11

Alpha Tau Medical Ltd - One Associated Grade 3 Serious Adverse Event Was Observed, Since Resolved

THOMSON REUTERS
·
May 11

Alpha Tau Medical Ltd - No Unanticipated Serious Adverse Events Observed as of May 3, 2026

THOMSON REUTERS
·
May 11

Alpha Tau completes enrollment in pivotal ReSTART trial for recurrent skin cancer

Reuters
·
May 08

Alpha Tau Completes Patient Enrollment in Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha Dart® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

THOMSON REUTERS
·
May 08

Alpha Tau treats first patient with Alpha DaRT in Italy

TIPRANKS
·
May 08

Alpha Tau Medical Ltd: Successfully Treats First Pancreatic Cancer Patient in Italy With Alpha Dart

THOMSON REUTERS
·
May 07

Alpha Tau launches Italy feasibility study of Alpha DaRT in pancreatic cancer

Reuters
·
May 07

Alpha Tau to present Alpha DaRT-pembrolizumab head and neck cancer trial data at AHNS 2026

Reuters
·
May 05

Alpha Tau presents updated results from two clinical trials of Alpha DaRT

TIPRANKS
·
May 04

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha Dart® Pancreatic Cancer Trials Presented at Ddw 2026

THOMSON REUTERS
·
May 04

Alpha Tau reports 100% local disease control in pooled Alpha DaRT pancreatic trials

Reuters
·
May 04

BRIEF-Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing

Reuters
·
Apr 28

Alpha Tau files $300M mixed securities shelf

TIPRANKS
·
Apr 28

Alpha Tau Medical Ltd - May Sell up to $100 Mln Ordinary Shares Under Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
Apr 28

Alpha Tau pancreatic cancer Alpha DaRT pooled data accepted for ASCO presentation

Reuters
·
Apr 27

Alpha Tau says FDA approves IDE supplement expanding pancreatic cancer IMPACT trial

Reuters
·
Apr 23